Medium-sized DongKwang Pharm successfully avoids KRW 10 billion ‘Cancidas’ patent
A medium pharmaceutical company DongKwang Pharmaceutical raised a chance for the early launch of Cancidas(caspofungin acetate, MSD Korea), antifungal, through avoiding its patent alone.
Since it is the patent other companies are also struggling with even in the U.S., particularly, the result has...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
